COST-EFFECTIVENESS OF RITUXIMAB-BASED CHEMOTHERAPY COMBINATIONS FOR THE INTIAL THERAPY OF FOLLICULAR LYMPHOMA

被引：0
|
作者：
Shah, G. [1 ]
Winn, A. [2 ]
Kumar, A. [3 ]
Lin, P. [3 ]
Parsons, S. [3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ North Carolina Chapel Hill, Chapel Hill, NC USA
[3] Tufts Med Ctr, Boston, MA USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY70
引用
收藏
页码：A221 / A221
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS AND COST-UTILITY ANALYSES OF POLATUZUMAB VEDOTIN WITH RITUXIMAB AND CHEMOTHERAPY VS RITUXIMAB AND CHEMOTHERAPY IN TREATING NAIVE DIFFUSE LARGE B-CELL LYMPHOMA IN ITALY
    Bellone, M.
    Pradelli, L.
    Ghislieri, D.
    VALUE IN HEALTH, 2022, 25 (12) : S75 - S76
  • [42] Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
    Ogura, Michinori
    Tobinai, Kensei
    Hatake, Kiyohiko
    Uchida, Toshiki
    Kasai, Masanobu
    Oyama, Takashi
    Suzuki, Tatsuya
    Kobayashi, Yukio
    Watanabe, Takashi
    Azuma, Teruhisa
    Mori, Masakazu
    Terui, Yasuhito
    Yokoyama, Masahiro
    Mishima, Yuko
    Takahashi, Shunji
    Ono, Chiho
    Ohata, Junko
    CANCER SCIENCE, 2010, 101 (08) : 1840 - 1845
  • [43] Rituximab maintenance therapy in follicular lymphoma
    Forstpointner R.
    Dreyling M.
    Current Hematologic Malignancy Reports, 2007, 2 (4) : 213 - 218
  • [44] RITUXIMAB BASED CHEMOTHERAPY FOR PEDIATRIC FOLLICULAR LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE
    Kumar, Riten
    Galardy, Paul
    Dogan, Ahmet
    Rodriguez, Vilmarie
    Khan, Shakila
    PEDIATRIC BLOOD & CANCER, 2010, 54 (06) : 821 - 821
  • [45] Cost-utility analysis of maintenance therapy with rituximab for follicular lymphoma in Brazil
    Chiattone, C. S.
    Saggia, M. G.
    Santos, E. A.
    VALUE IN HEALTH, 2007, 10 (06) : A337 - A338
  • [46] Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission
    Hayslip, John W.
    Simpson, Kit N.
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (03): : 166 - 170
  • [47] Frontline Rituximab Monotherapy Induction Versus a Watch and Wait Approach For Asymptomatic Advanced Stage Follicular Lymphoma: A Cost-Effectiveness Analysis
    Prica, Anca
    Chan, Kelvin K. W.
    Cheung, Matthew C.
    BLOOD, 2013, 122 (21)
  • [48] COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA. PRELIMINARY RESULTS
    Sabater, E.
    Rueda, A.
    Salar, A.
    Lopez-Guillermo, A.
    Oyagueez, I.
    Collar, J. M.
    HAEMATOLOGICA, 2014, 99 : 487 - 488
  • [49] Cost-effectiveness of rituximab maintenance treatment versus autologous stem cell transplantation (ASCT) in patients with relapsed follicular lymphoma (FL).
    Leppae, Sirpa
    Linna, Miika
    Nyman, Heidi
    Taimela, Eeva
    BLOOD, 2006, 108 (11) : 952A - 952A
  • [50] Different Role of PET-CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab-Based Chemotherapy and Chemo-Free Immunotherapy
    Wang, Nan
    Huang, Xin-Yun
    Jiang, Xu-Feng
    Wang, Li
    Cheng, Shu
    Xu, Peng-Peng
    Dong, Lei
    Ou-Yang, Bin-Shen
    Mu, Rong-Ji
    Li, Chen
    Zhao, Yan
    Feng, Yan
    Dou, Hong-Jing
    Zheng, Zhong
    Zhao, Wei-Li
    HEMATOLOGICAL ONCOLOGY, 2025, 43 (01)
12345